These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 9184403

  • 1. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
    Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G.
    Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
    [Abstract] [Full Text] [Related]

  • 2. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
    Devignes J, de Maistre E, Grosjean S, Walter AF, Hacquard M, Mulot A, Longrois D, Carteaux JP, Lecompte T.
    Ann Biol Clin (Paris); 2005 May; 63(2):201-8. PubMed ID: 15771978
    [Abstract] [Full Text] [Related]

  • 3. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
    Choi TS, Khan AI, Greilich PE, Kroll MH.
    Am J Clin Pathol; 2006 Feb; 125(2):290-5. PubMed ID: 16393689
    [Abstract] [Full Text] [Related]

  • 4. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
    Pötzsch B, Hund S, Madlener K, Unkrig C, Müller-Berghaus G.
    Thromb Res; 1997 Jun 01; 86(5):373-83. PubMed ID: 9211628
    [Abstract] [Full Text] [Related]

  • 5. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II.
    Koster A, Hansen R, Grauhan O, Hausmann H, Bauer M, Hetzer R, Kuppe H, Mertzlufft F.
    J Cardiothorac Vasc Anesth; 2000 Jun 01; 14(3):249-52. PubMed ID: 10890474
    [Abstract] [Full Text] [Related]

  • 6. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia.
    Longrois D, de Maistre E, Bischoff N, Dopff C, Meistelman C, Angioï M, Lecompte T.
    Can J Anaesth; 2000 Mar 01; 47(3):255-60. PubMed ID: 10730738
    [Abstract] [Full Text] [Related]

  • 7. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device.
    Koster A, Loebe M, Hansen R, Bauer M, Mertzlufft F, Kuppe H, Hetzer R.
    J Thorac Cardiovasc Surg; 2000 Jun 01; 119(6):1278-83. PubMed ID: 10838548
    [Abstract] [Full Text] [Related]

  • 8. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.
    Sucker C, Zotz RB, Görlinger K, Hartmann M.
    Acta Anaesthesiol Scand; 2008 Mar 01; 52(3):358-62. PubMed ID: 18205897
    [Abstract] [Full Text] [Related]

  • 9. Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization.
    Iqbal O, Tobu M, Aziz S, Gerdisch M, Da Valle M, Demir M, Hoppensteadt DA, Ahmad S, Walenga JM, Fareed J.
    J Card Surg; 2005 Mar 01; 20(1):42-51. PubMed ID: 15673409
    [Abstract] [Full Text] [Related]

  • 10. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays.
    Nurmohamed MT, Berckmans RJ, Morriën-Salomons WM, Berends F, Hommes DW, Rijnierse JJ, Sturk A.
    Thromb Haemost; 1994 Nov 01; 72(5):685-92. PubMed ID: 7900075
    [Abstract] [Full Text] [Related]

  • 11. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient.
    Nowak G, Bucha E, Brauns I, Czerwinski R.
    Wien Klin Wochenschr; 1997 May 23; 109(10):354-8. PubMed ID: 9200807
    [Abstract] [Full Text] [Related]

  • 12. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients.
    Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F.
    J Cardiothorac Vasc Anesth; 2000 Jun 23; 14(3):243-8. PubMed ID: 10890473
    [Abstract] [Full Text] [Related]

  • 13. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
    Huhle G, Hoffmann U, Hoffmann I, Harenberg J, Heene DL.
    Dtsch Med Wochenschr; 2000 Jun 02; 125(22):686-91. PubMed ID: 10874895
    [Abstract] [Full Text] [Related]

  • 14. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
    Despotis GJ, Hogue CW, Saleem R, Bigham M, Skubas N, Apostolidou I, Qayum A, Joist JH.
    Anesth Analg; 2001 Jul 02; 93(1):28-32. PubMed ID: 11429333
    [Abstract] [Full Text] [Related]

  • 15. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
    Kher A, Gouin I, Samama MM.
    Ann Biol Clin (Paris); 2000 Jul 02; 58(5):575-9. PubMed ID: 11022100
    [Abstract] [Full Text] [Related]

  • 16. Hirudin-based anticoagulant strategy during isolated limb perfusion in a patient with heparin-induced thrombocytopenia.
    Lindemann W, Richter S, Schilling MK.
    Melanoma Res; 2005 Aug 02; 15(4):287-90. PubMed ID: 16034307
    [Abstract] [Full Text] [Related]

  • 17. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
    Moser M, Ruef J, Peter K, Kohler B, Gulba DC, Paterna N, Nordt T, Kübler W, Bode C.
    J Thromb Thrombolysis; 2001 Oct 02; 12(2):165-9. PubMed ID: 11729368
    [Abstract] [Full Text] [Related]

  • 18. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
    Kim H, Szlam F, Tanaka KA, van de Locht A, Ogawa S, Levy JH.
    Anesth Analg; 2012 Aug 02; 115(2):244-52. PubMed ID: 22584552
    [Abstract] [Full Text] [Related]

  • 19. Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass.
    Fabrizio MC.
    J Extra Corpor Technol; 2001 May 02; 33(2):117-25. PubMed ID: 11467439
    [Abstract] [Full Text] [Related]

  • 20. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia.
    Guy S, Kitchen S, Laidlaw S, Cooper P, Woolley A, Maclean R.
    Br J Haematol; 2008 Jul 02; 142(3):466-8. PubMed ID: 18510685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.